Professor Dore led the first international hepatitis C therapy trials to include study populations of people who inject drugs.
From the Australian Museum:
People who inject drugs are a key population affected by hepatitis C, but often excluded from therapy trials due to perceived poor compliance. Professor Gregory Dore has led the first international trials to include a range of study populations from this marginalised group. His research informs clinical practices and improves these groups' access to hepatitis C therapy globally.